Carcinoma News and Research

RSS
Carcinoma is cancer that begins in the skin or in tissues that line or cover internal organs.
Surgeon uses radiotracers to detect the ganglion through which tumour attempts to spread

Surgeon uses radiotracers to detect the ganglion through which tumour attempts to spread

Neoprobe's Lymphoseek Phase 3 trial data presented at SNM annual meeting

Neoprobe's Lymphoseek Phase 3 trial data presented at SNM annual meeting

MDxHealth extends agreement with Merck for use of MGMT assay in brain cancer trials

MDxHealth extends agreement with Merck for use of MGMT assay in brain cancer trials

Agensys, Seattle Genetics to co-develop second antibody-drug conjugate for multiple solid tumors

Agensys, Seattle Genetics to co-develop second antibody-drug conjugate for multiple solid tumors

Patient enrollment complete in cilengitide Phase III study against glioblastoma

Patient enrollment complete in cilengitide Phase III study against glioblastoma

NYU Cancer Institute scientists present new research findings at ASCO 2011

NYU Cancer Institute scientists present new research findings at ASCO 2011

OncoSec announces additional evaluation of ElectroImmunotherapy Phase I trial on melanoma

OncoSec announces additional evaluation of ElectroImmunotherapy Phase I trial on melanoma

Independent investigators report Lymphoseek meets all endpoints in NEO3-09 Phase 3 study

Independent investigators report Lymphoseek meets all endpoints in NEO3-09 Phase 3 study

Increases in VEGF-family markers in metastatic colorectal cancer patients associated with Avastin resistance

Increases in VEGF-family markers in metastatic colorectal cancer patients associated with Avastin resistance

Exelixis reports encouraging interim data from cabozantinib phase 2 trial for metastatic CRPC

Exelixis reports encouraging interim data from cabozantinib phase 2 trial for metastatic CRPC

Tikcro reports net loss of $30,000 for first quarter 2011

Tikcro reports net loss of $30,000 for first quarter 2011

Global gene therapy market to reach $300 million by 2015

Global gene therapy market to reach $300 million by 2015

Genentech's Avastin, chemotherapy Phase III combination study data on ovarian cancer presented at ASCO

Genentech's Avastin, chemotherapy Phase III combination study data on ovarian cancer presented at ASCO

New data from Argos AGS-003, sunitinib Phase 2 combination study on RCC presented at ASCO

New data from Argos AGS-003, sunitinib Phase 2 combination study on RCC presented at ASCO

ImmunoGen's IMGN901 Phase I trial data on multiple myeloma presented at ASCO 2011

ImmunoGen's IMGN901 Phase I trial data on multiple myeloma presented at ASCO 2011

Promising results from Exelixis' cabozantinib phase 2 trial against metastatic ovarian cancer

Promising results from Exelixis' cabozantinib phase 2 trial against metastatic ovarian cancer

Alnylam's ALN-VSP Phase I trial data on liver cancer presented at ASCO 2011

Alnylam's ALN-VSP Phase I trial data on liver cancer presented at ASCO 2011

Positive results from Plexxikon's vemurafenib Phase 2 and 3 trial against metastatic melanoma

Positive results from Plexxikon's vemurafenib Phase 2 and 3 trial against metastatic melanoma

Delayed treatment could prove effective in certain medical conditions

Delayed treatment could prove effective in certain medical conditions

Bexarotene and erlotinib drugs effective in treating advanced lung cancer

Bexarotene and erlotinib drugs effective in treating advanced lung cancer

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.